title: Systemic inflammation, blood pressure, and stroke outcome.
abstract: Hypertension is the most important modifiable risk factor for ischemic stroke, and antihypertensive treatment is of paramount importance to reduce the incidence of stroke mortality and morbidity. The significance and best management of hypertension during the first hours after stroke onset, however, are still matters of debate. Cerebral ischemia results in a complex inflammatory cascade; inflammatory mechanisms are also important participants in the pathophysiology of hypertension. There has been a convergence of evidence that is important to consider in managing systemic blood pressure after stroke to ensure an optimal outcome. The identification of useful markers will allow progress in our ability to treat blood pressure in the acute phase of a stroke. The determination of levels of C-reactive protein, an acute-phase inflammation marker, may help to guide our approach in the management of blood pressure in acute ischemic stroke. Whether this target will be useful in the development of risk prediction strategies or therapies for the treatment of stroke in humans is far from clear.
authors.affiliation: Neurological Service, San Camillo de' Lellis General Hospital, Rieti, Italy. mariodinapoli@katamail.com
authors.forename: Mario
authors.initials: M
authors.lastname: Di Napoli
authors.forename: Francesca
authors.initials: F
authors.lastname: Papa
mesh_terms: D000208:Acute Disease; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure; D002545:Brain Ischemia / Q000503:physiopathology*; D002097:C-Reactive Protein / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007249:Inflammation / Q000503:physiopathology; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000503:physiopathology*; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D002097:C-Reactive Protein